Micromem Technologies Inc. Provides an Update on its Business Initiatives

Micromem Technologies Inc. Provides an Update on its Business Initiatives

PR Newswire

TORONTO and NEW YORK, April 8 /PRNewswire/ – Micromem Technologies Inc., (Micromem, the Company”) (OTC BB: MMTIF) (CNSX: MRM) and its wholly-owned subsidiary, Micromem
Applied Sensor Technologies, Inc. (MAST) (www.mastinc.com), provide the following update on its business initiatives:

1. The Company has posted on its website, www.micromeminc.com, a video link that demonstrates its fully operational medical device.
The company is pleased with the performance of the device.

   
2. The Company announced a development agreement with an international oil
company on March 4, 2011. It continues its development activity and has
successfully completed the next milestone for the client.

   
  The contract involves the detection of tiny nanoparticles at a very low
concentration. Tests being conducted on Micromem’s 250 nm Hall Sensor
using 16 nm nanomagnetic particles resulted in the Company’s ability to
detect and discern down to 3 particles in solution at 1.6KHz. This
ability to validate the detection limit of Micromem’s sensor in terms
of noise-equivalent and minimum number of particles is critical to our
client and the success of the project.

   
  The Company is currently under a non disclosure agreement that prevents
the company from disclosing the name of the client and details
pertaining to the contract.

   
3. As a result of the continued development of Micromem’s patented
technology, the Company announced today they are now working with two
partners, Diagnostic Biosensors (www.diagnosticbiosensors.com) and MicroPlumbers Microsciences LLC (www.microplumbers.com), as part of its push into the Lab-on-a-Chip (“LOC”) market.
   
  Micromem is targeting both medical and oil and gas exploration clients
with this technology. The expected advantages include portability,
rapid assay times and smaller sample requirements. Other advantages are
that conventional laboratory analysis which is time consuming, tedious,
and requires expensive equipment and highly trained personnel.
Bench-top analysis in LOCs can be several times cheaper and faster.
   
  Diagnostic Biosensors is dedicated to the idea that clinical laboratory
diagnostic capabilities can be delivered directly to consumers in an
economical and effective way. These quantitative biosensors are highly
sensitive and inexpensive because the detectors are tiny integrated
circuit chips.
   
  MicroPlumbers apply advanced mathematical modeling tools to solve
complex problems of microfluidic device design. Their experience in
microfluidics and microfabrication date back to the early 1990s and
includes the development of micropumps, microvalves, microfluidic
assays.

   
4. The Company continues to pursue all previously announced business
initiatives and will provide an update to shareholders as new material
information becomes available.

About Micromem Technologies Inc. and MASTInc:

MASTInc is a wholly owned U.S.-based subsidiary of Micromem Technologies
Inc., a publicly traded (OTC: MMTIF) (CNSX:MRM) fabless semiconductor company with headquarters in Toronto,
Canada
and an office in New York City. Micromem holds and continues to
develop a broad-based patent portfolio of Magnetoresistive Random
Access Memory (MRAM) and magnetic sensor technologies. Micromem’s MRAM
patents create a solution for performance driven, radiation hard,
non-volatile memory applications. MASTInc is focused on business
development efforts and is working on the launch of sensory products
for use in both defense and consumer applications. Its first product,
GC-0301, is far superior to the competition with over 200 V/T, making
it one of the most sensitive hall sensors on the market without the
need for external amplification. MASTInc is working with companies that
have large-scale capabilities and expects to sign contracts in the
coming quarters.

Safe Harbor Statement

This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause the Company’s actual
results to differ materially from those projected in such
forward-looking statements. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include, our inability to obtain additional financing on
acceptable terms, risk that our products and services will not gain
widespread market acceptance; continued consumer adoption of digital
technology, inability to compete with others who provide comparable
products, the failure of our technology, inability to respond to
consumer and technological demands, inability to replace significant
customers; seasonal nature of our business and other risks detailed in
our filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. We undertake no obligation to
publicly update or revise any forward-looking statements. When used in
this document, the words “believe,” “expect,” “anticipate,” “estimate,”
“project,” “plan,” “should,” “intend,” “may,” “will,” “would,”
“potential,” and similar expressions may be used to identify
forward-looking statements.

The CNSX or any other securities regulatory authority has not reviewed
and does not accept responsibility for the adequacy or accuracy of this
press release that has been prepared by management.

Listing: NASD OTC-Bulletin Board – Symbol: MMTIF
             :CNSX – Symbol: MRM
Shares issued: 97,849,511
SEC File No: 0-26005

 

 

SOURCE Micromem Technologies Inc.


Be the first to comment

Leave a Reply